• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Heart Online ahead of print. Do Underlying Cardiovascular Diseases Have Any Impact on Hospitalised Patients With COVID-19?

tetano

Editor, Senior Moderator
Heart


. 2020 May 25;heartjnl-2020-316909.
doi: 10.1136/heartjnl-2020-316909. Online ahead of print.
Do Underlying Cardiovascular Diseases Have Any Impact on Hospitalised Patients With COVID-19?


Jixiang Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Shimin Lu[SUP] #[/SUP][SUP] 1 [/SUP], Xiaoli Wang[SUP] 2 [/SUP], Xuemei Jia[SUP] 1 [/SUP], Jiao Li[SUP] 1 [/SUP], Hongbo Lei[SUP] 3 [/SUP], Zhengru Liu[SUP] 1 [/SUP], Fei Liao[SUP] 1 [/SUP], Mengyao Ji[SUP] 1 [/SUP], Xiaoguang Lv[SUP] 1 [/SUP], Jian Kang[SUP] 1 [/SUP], Shan Tian[SUP] 1 [/SUP], Jingjing Ma[SUP] 4 [/SUP], Dandan Wu[SUP] 5 [/SUP], Yang Gong[SUP] 6 [/SUP], Yu Xu[SUP] 7 [/SUP], Weiguo Dong[SUP] 8 [/SUP]



Affiliations

Abstract

Objectives: An outbreak of the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has sickened thousands of people in China. The purpose of this study was to explore the early clinical characteristics of COVID-19 patients with cardiovascular disease (CVD).
Methods: This is a retrospective analysis of patients with COVID-19 from a single centre. All patients underwent real-time reverse transcription PCR for SARS-CoV-2 on admission. Demographic and clinical factors and laboratory data were reviewed and collected to evaluate for significant associations.
Results: The study included 541 patients with COVID-19. A total of 144 (26.6%) patients had a history of CVD. The mortality of patients with CVD reached 22.2%, which was higher than that of the overall population of this study (9.8%). Patients with CVD were also more likely to develop liver function abnormality, elevated blood creatinine and lactic dehydrogenase (p<0.05). Symptoms of sputum production were more common in patients with CVD (p=0.026). Lymphocytes, haemoglobin and albumin below the normal range were pervasive in the CVD group (p<0.05). The proportion of critically ill patients in the CVD group (27.8%) was significantly higher than that in the non-CVD group (8.8%). Multivariable logistic regression analysis revealed that CVD (OR: 2.735 (95% CI 1.495 to 5.003), p=0.001) was associated with critical COVID-19 condition, while patients with coronary heart disease were less likely to reach recovery standards (OR: 0.331 (95% CI 0.125 to 0.880), p=0.027).
Conclusions: Considering the high prevalence of CVD, a thorough CVD assessment at diagnosis and early intervention are recommended in COVID-19 patients with CVD. Patients with CVD are more vulnerable to deterioration.

Keywords: cardiac rehabilitation; cardiac risk factors and prevention; electronic medical records; hypertension.
 
Back
Top Bottom